#USA #San Diego #Halozyme #Hypercon #Oruka

Halozyme and Oruka Announce Groundbreaking Global Collaboration

Halozyme Therapeutics, Inc. and Oruka Therapeutics, Inc. joined forces on May 6, 2026, to form a global collaboration aimed at revolutionizing the treatment of psoriasis and related inflammatory diseases through innovative drug delivery technology. This partnership marks a significant milestone for both companies as they work towards utilizing Halozyme's proprietary Hypercon™ technology with Oruka's ORKA-001, a therapeutic designed to tackle chronic skin conditions.

The Significance of Hypercon™ Technology

Hypercon™ is an advanced microparticle technology that enhances the efficacy of drug delivery by allowing for hyperconcentration of biologics. This pioneering approach reduces the injection volume required for medications, making the administration process more patient-friendly. The collaboration not only allows Oruka to use this state-of-the-art technology for ORKA-001 but also provides the potential to explore additional therapeutic targets in the future.

Dr. Helen Torley, the President and CEO of Halozyme, expressed enthusiasm about the partnership: "We are pleased to announce our second Hypercon collaboration this year, further validating the broad applicability and partner interest in this technology." Such endorsements highlight the integral role that innovative technologies like Hypercon™ play in elevating patient care.

A Patient-Centric Approach

Lawrence Klein, CEO of Oruka Therapeutics, reiterated the importance of this partnership in offering effective solutions for patients affected by chronic skin diseases. Klein remarked, "We are excited to partner with Halozyme's Hypercon in our pursuit to offer the best possible medicines to people with chronic skin conditions like psoriasis." This sentiment underscores a shared commitment between the two companies to prioritize patient welfare and convenience.

Financial Implications and Future Potential

As part of this agreement, Oruka will provide Halozyme with an upfront payment along with the possibility of future milestone payments tied to the progression and success of the collaboration. Additionally, Halozyme stands to gain royalties from the net sales of products developed utilizing the Hypercon™ technology.

Both companies are optimistic about the financial prospects of this venture as they embark on a journey to reshape the treatment landscape for psoriasis and its related disorders. Halozyme has established its reputation as a biopharmaceutical innovator with its ENHANZE® technology, which has positively impacted the lives of over one million patients, facilitating the administration of therapeutics administered subcutaneously.

About Halozyme and Oruka

Halozyme Therapeutics has carved its niche in the biopharmaceutical realm by focusing on innovative solutions that enhance the treatment experience for patients. With a portfolio that includes several commercialized products licensed to major pharmaceutical firms, Halozyme continues to expand its influence in the medical field.

On the other hand, Oruka Therapeutics is committed to developing novel biologics with the aim of transforming the treatment options available for chronic skin ailments. By focusing on high efficacy and reduced dosing frequency, Oruka aspires to grant patients the freedom they crave from persistent skin conditions.

What's Next?

With this collaboration, the future appears promising as Halozyme and Oruka work together to refine their respective technologies while driving advancements in patient treatment options. As the development of ORKA-001 progresses, patients and healthcare professionals alike eagerly await the innovative breakthroughs that are sure to come from this strategic alliance. This partnership not only represents a remarkable advancement in psoriasis treatment but also serves as an encouraging example of how technology can enhance the quality of life for patients globally.

For the latest updates on this collaboration and other developments in biopharmaceutical innovations, interested individuals can keep an eye on the official websites of both Halozyme and Oruka Therapeutics, as well as relevant health news outlets.